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Summary The effects on experimental melanoma of a combination of recombinant human tumour necrosis
factor alpha (rhTNFa) and carmustine (BCNU) were studied in vitro and in vivo. In vitro, BCNU alone was
cytotoxic to murine B16 melanoma cells, and at all concentrations of BCNU this toxicity was increased by the
addition of TNF. In vivo, BCNU and TNF, when given separately, caused tumour growth delay of B16
melanoma and of human melanoma xenografts in immune-deprived mice. The combination of TNF at low
dose 2.5 x I0 U kg-' = 122 ng kg-') with BCNU (35 mg kg-') resulted in significant growth delay (compared
with either drug alone) in B16 melanoma (P = 0.005). There was no significant increase in toxicity as assessed
by weight loss and peripheral blood counts. Experiments with human melanoma xenografts yielded similar
results (P = 0.001) but only at higher doses of TNF (1 x 106U kg-' = 489 ng kg-'). The enhancement of
BCNU cytotoxicity by TNF may be important if it can be translated into patients with melanoma. A
randomised study is now underway to investigate the clinical potential of this observation.
The treatment of patients with metastatic melanoma is dis-
appointing. Chemotherapy with single drugs such as dacar-
bazine (Comis, 1976) and the nitrosoureas (Ahmann, 1976)
achieves response rates of about 20%. Combination chemo-
therapy and high dose treatment can increase response rates
but do not prolong survival (Lakhani et al., 1990). Hence
new strategies for the management of disseminated mela-
noma need to be devised.
Melanoma has, for some years, been considered a good
candidate for treatment with biological agents. Intralesional
therapy with Bacillus Calmette Guerin (BCG) caused regres-
sion of dermal disease (Rosenberg et al., 1982) but local
therapy had little impact on the management of patients with
disseminated disease. Systemic biological therapy using
agents such as alpha interferon or interleukin 2 also achieved
a response rate of up to 25% (Creagen et al., 1987; Rosen-
burg et al., 1987).
Tumour necrosis factor (TNF) is a polypeptide originally
identified in the serum of BCG treated mice which were
subsequently exposed to endotoxin (Carswell et al., 1975).
The genes encoding both human and murine TNF have been
expressed in E. coli. The human and murine proteins are
79% homologous (Marmenout et al., 1985) and show little
species specificity in terms of biological effects. TNF alpha is
produced by activated macrophages (Mannel et al., 1980). A
closely related protein, lymphotoxin or TNF beta is pro-
duced by activated lymphocytes and has 30% homology with
TNF alpha (Pennica et al., 1984) and similar biological
activity. TNF apha has been more extensively investigated as
an anticancer agent than TNF beta. TNF is cytotoxic to
many murine and human tumour cells, including some mela-
noma cell lines, in vitro (Helson et al., 1975; Fransen et al.,
1975).
In vivo, local administration of TNF has caused complete
regression of some tumours (Haranaka et al., 1984). Com-
plete regression of syngeneic tumours and growth delay of
human tumour xenografts in immune deprived mice have
also been seen when TNF was used systemically (Haranaka
et al., 1984; Balkwill et al., 1986; Brouckaert et al., 1986;
Creasey et al., 1986). This included some human melanomas
grown as xenografts. The use of TNF as a single agent in
patients with cancer is limited because of systemic toxicity
(Selby et al., 1987) which occurs at doses which achieve
serum levels below those associated with regression of experi-
mental tumours in mice. The maximum tolerated intravenous
dose in phase I studies was 9 x I05 U (440pg) per m2 (Selby
et al., 1987).
In vitro TNF increases the cytotoxicity of anthracyclines
such as doxorubicin and podophyllotoxins such as etoposide
(Alexander et al., 1987). Actinomycin D increases the cyto-
toxicity of TNF. Thus the administration of cytotoxic drugs
in combination with TNF might increase the therapeutic
range against drug resistant tumours. We have investigated
the effect of TNF on the toxicity of carmustine (BCNU), a
nitosourea with activity against melanoma, on the murine
melanoma B16 in vitro and in vivo. Normal tissue toxicity
was monitored concomitantly to determine the therapeutic
index. The effects of BCNU and TNF (alone and in combin-
ation) on human melanoma xenografts in immune deprived
mice are also reported.
Materials and methods
Mice
Female C57 BL mice, aged 10-12 weeks, were used in all
experiments involving the murine B16 melanoma. Congeni-
tally athymic, specific pathogen free, male, 'nude' mice aged
6- 10 weeks (MRC, Mill Hill) were used in experiments
involving human tumour xenografts. Mice were kept, 4-5
per box, and fed and watered ad libitum. 'Nude' mice were
kept in sterile conditions in negative pressure isolators.
Drugs
Carmustine (BCNU) (Bristol Myers) was dissolved in abso-
lute alcohol at a concentration of 100 mg ml . This solution
was dissolved in 0.9% saline just before injection for doses of
35 mg kg-'. This dose was selected as the maximum tolerated
dose in mice (Marsh, 1986). Recombinant human tumour
necrosis factor alpha (rhTNFa) was a gift from the Asahi
Chemical Company Ltd. It was supplied at a concentration
of I x IO' U ml-'. Of this, 99% of the total protein was
TNF with bacterial DNA less than lOOpgmg-1. TNF was
reconstituted in a sterile 0.1% gelatin/0.9% saline solution
and stored at a concentration of 106U ml-' at - 20C. Ali-
quots were thawed and further diluted in 0.9% saline immed-
iately before use. The biological activity of TNF was con-
firmed using the L cell assay (Zacharchuk et al., 1983). C57
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BI mice normally tolerated up to 1 x I07U (4.91g) per kg
TNF i.p. However, C57 Bi mice bearing B16 melanoma were
more sensitive to acute systemic toxicity of TNF and the
maximum tolerated dose was limited to 2.5 x I05 U (122 ng)
per kg (Table I). This dose was used in all B16 experiments
in vivo. No late toxicity was seen in surviving animals.
Experiments were terminated when the rate of tumour re-
growth was similar to the rate of growth of untreated
tumours.
Tumours
B16 melanoma was passaged in C57 BL mice by inoculation
of a bolus of cells subcutaneously in a shaved site on the
flanks bilaterally. The human melanoma xenografts (HX47,
HX34, HX118) were derived from primary human tumour
from patients at the Royal Marsden Hospital, Sutton. The
tumours were used between passage 12 and 20. For passage,
animals were killed under anaesthetic, the tumour excised
and tumour tissue divided into cubes approximately 1 mm in
length using a crossed scalpel technique. Recipient mice were
anaesthetised and the tumour was implanted bilaterally in the
flanks through a skin incision.
Statistics
No assumption was made about the normality of the distri-
bution of the data. A non-parametric test (Mann-Whitney
U test) was used throughout comparing the growth delays in
tumour growth delay experiments and the weights on day X
compared with those on day 0.
Experimental design
In vitro assay The sensitivity of B16 melanoma cells to
BCNU in vitro was measured using a clonogenic assay. Two
hundred cells were plated in triplicate for each dose point
into 60 mm diameter plastic Petri dishes in RPMI-1640
(Flow, Labs Irvine, UK) supplemented with 15% fetal calf
serum, 20mM HEPES buffer, 100 unitsml-' penicillin and
lOO1 gml-' streptomycin. The plating efficiency was 50%.
After attachment the medium was removed from the dishes
and replaced with Dulbecco's phosphate buffered saline 'A'
(PBSA) containing BCNU at the concentrations indicated in
the text. Cultures were incubated at 37°C for I h at which
time this medium was removed from the dishes and replaced
with 2 ml offresh growth medium. To determine the effect of
TNF on the toxicity of BCNU, 2,000 (I ng) units ml-' TNF
was added to the growth medium after the removal of
BCNU. Control cultures were treated with PBSA before
changing to fresh growth medium. Cultures were incubated
for 10- 12 days at 37TC in an atmosphere of 5% C02, 10%
02 and 85% N2. At this time the medium was discarded from
the dishes, the cells fixed in ethanol and stained with methy-
lene blue. Colonies were counted using a colony counter
(Anderson, UK).
In vivo All animals in a single experiment were inoculated
on the same day. Experiments were started when tumour
diameters reached 0.3-0.5 cm. Tumours were measured with
plastic calipers and volumes calculated by the formula
(assuming spheroidal tumours):
Table I The toxicity ofintraperitoneal rhTNFa to normal and tumour
bearing mice
Mortaliti' by group
Nude +
Dose (Ukg') C57 C57 + B16 Nude Hx 118
2.5 x 105 0/5 0/5 0/5 0/5
5 x 105 0/5 1/5 0/5 0/5
1 x 106 0/5 4/4 0/5 0/5
5 x 106 0/5 * 0/4 0/4
I x 1lo 0/5 * 0/4 1/3
*These doses were not given as 100% mortality at I x 106 was
confirmed in repeat experiment (4/4 mice).
7t LD2
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where L is the greatest diameter and D the diameter at right
angles to L.
Animals were ranked according to tumour size and
allocated to groups so each group contained the same range
of volumes. Each group contained 4-5 mice (8-10 tumours).
Animals were identified by ear tags and the groups were
distributed throughout the boxes so that tumour
measurements could be made in a 'blind' fashion.
Drugs were injected intraperitoneally rather than int-
ravenously as repeated injections were to be used. Control
animals received carrier solution. BCNU, 35 mg kg-' was
injected on day 0 and TNF was injected daily from day 0 for
5 days. Response was assessed by growth delay (Kopper &
Steel, 1975). The tumour volume at any time 't' (V,) was
compared with the volume before treatment (V0). The ratio
V,/V0 was calculated at each time point and the mean and
standard error calculated for each treatment group. Mean
V,/V0 (± s.e.) for each group was plotted as a function of
time to obtain growth curves. Tumour growth delay was
expressed as the difference in time taken between untreated
and treated groups of tumours to double in volume. In each
group animals were killed when the tumour was greater than
1.5 cm or if there were signs of ulceration.
In some experiments animals were weighed concurrently
with tumour measurements and the mean weight (± s.e.) of
each group expressed as a ratio to the starting weight.
Peripheral blood samples were taken from tail veins to assess
haematological toxicity. Capillary samples of 20,il were
taken into EDTA and the tail tip ligated and sterilised.
Samples were counted on a Coulter S Plus and a multiplica-
tion factor (7.5-fold) used to determine actual WBC. Blood
samples were performed on non-tumour bearing mice.
Results
In vitro
The effects of BCNU as a single agent and in combination
with TNF on B16 cells in vitro are shown in Figure 1. TNF
alone had no effect on B16 in vitro. BCNU reduced the
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Figure 1 Effect of TNF (2,000Uml-') on BCNU cytotoxicity
to B16 melanoma cells in vitro (±s.e.m.). Filled symbols =with
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surviving fraction of B16 cells over the dose range measured
(between 10 and 30pM). At 30tLM BCNU the surviving
fraction was reduced to 0.1 of control untreated values.
When TNF, 2,000 U (1 ng) per ml, was added, there was a
further reduction in the surviving fraction at all doses of
BCNU. With 30ltM BCNU and 2,000 U ml-' TNF the sur-
viving fraction was reduced to approximately one tenth of
the value achieved with BCNU alone.
In vivo
The growth delays expressed as doubling times achieved with
TNF and BCNU alone, and in combination for B16
melanoma are presented in Table II. A significant delay in
doubling time was obtained with TNF alone (P = 0.001),
BCNU alone (P = 0.001) and with the combination treat-
ment (P = 0.001). However, the combination of TNF and
BCNU was significantly better than either TNF alone
(P = 0.001) or BCNU alone (P = 0.013). No cures were seen
in any experiment and in all experiments tumour regrowth
occurred. The effect of treatments on body weight is shown
in Figure 2. Control animals did not lose weight. Significant
weight loss at day 3 was seen in the group receiving TNF
alone (P = 0.05), and in the group receiving combination
treatment (P = 0.005), although the increased weight loss in
the combination group was not significantly greater than in
the group receiving TNF alone. On day 10 weight loss in the
group receiving TNF and BCNU was significantly greater
than in the group receiving either TNF alone (P = 0.001) or
BCNU alone (P = 0.025). All animals had regained their
starting weight by the end of the experiment.
The effect of treatments on peripheral white cell count
(WBC) are shown in Figure 3. BCNU as a single agent
caused prolonged neutropenia with a nadir at day 7 and
recovery to control values by day 30. TNF did not alter
WBC. The addition of TNF to BCNU did not alter the nadir
or pattern of recovery of WBC induced by BCNU.
Table II Times taken in days for tumour to double in volume
Control TNF alone BCNU alone Combination
Expt ia 2.0 3.3 4.0 13.6
Expt 2a 1.5 4.8 3.0 9.6
Expt 3a 2.5 5.0 4.1 12.6
Expt 4a 2.0 2.7 12.0 12.0
Expt5a 2.5 7.1 10.7 13.2
Expt 6a 2.0 4.0 4.0 10.5
HX47b 8 13 17 21
HX47b 7 8 11 18
HX34b 6 10 14 18
HX118b 8 8 8 14
"B16 melanoma in C57B1 mice. bThree human melanoma xenografts
in immune-deprived mice.
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Figure 2 Mean body weight (±s.e.m.) expressed as a ration of
weight on day 0. 0 = control, A = BCNU 35 mg kg-',
0 = TNF 2.5 x 105 U kg-', * = combination TNF + BCNU.
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Figure 3 Effect of TNF and BCNU (±s.e.m.) on peripheral
white cell count. * = control, A = TNF 2.5 x 105U kg-',
O = BCNU 35 mg kg-', * = combination TNF + BCNU.
Immune deprived mice bearing human melanoma xeno-
grafts tolerated higher doses of TNF than C57 BL mice with
B16 melanomas (Table I) and a dose of I x 106 U (489 ng)
per kg was used in xenograft experiments. The results of
experiments on three different xenografts are shown in Table
II. The delay in doubling time was not significant with TNF
alone (P = 0.057) but BCNU did cause significant growth
delay (P = 0.029). There was significant growth delay with
combination treatment (P = 0.014) and this was significantly
longer than the delays seen with BCNU alone (P = 0.029).
When the schedule of TNF was altered to 1 x 106 U (489 ng)
per kg b.d. there was further enhancement of growth delay
(Figure 4). In this experiment the dose of BCNU was con-
stant. Figure 4a represents TNF once daily and Figure 4b
shows the enhancement of growth delay with twice daily
TNF. No toxicity was observed in these animals.
Discussion
These results have shown that the cytotoxic activity of
BCNU on B16 melanoma cells in vitro was enhanced by the
addition of TNF across a range of concentrations of BCNU.
TNF in combination with BCNU increased the growth delay
of the B16 melanoma compared with that seen using either
BCNU or TNF alone.
The addition of TNF to BCNU did not result in increased
toxicity as measured by the peripheral blood count. Although
mice receiving combination treatment had weight loss of up
to 20%, there were no toxic deaths, and all mice regained
their starting weight by the end of the experiment. Enhanced
growth delay in the absence of significant toxicity represents
an improvement in the therapeutic index. Weight gain was
concurrent with tumour regrowth and may suggest that fac-
tors involved in mediating tumour regression may also be
involved mediating weight loss in these animals. TNF itself
has been implicated as a mediator of cachexia (Cerami et al.,
1985) but no significant weight loss was seen in the group
receiving TNF alone compared with untreated control
animals.
The enhanced antitumour effect with combination treat-
ment was unlikely to be caused by altered BCNU phar-
macokinetics as the addition of TNF did not affect the
pattern of myelosuppression after BCNU. TNF may affect
tumour vasculature (Nawroth & Stern, 1986) and hence drug
permeability, but in these experiments BCNU was given with
the initial dose of TNF making this explanation less likely.
The in vitro data suggest that TNF has a direct effect on the
cytotoxicity of BCNU. Similar potentiation of drug-induced
cytotoxicity by TNF in vitro and in vivo has been reportedCARMUSTINE ENHANCED BY rhTNFa 779
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Figure 4 Tumour growth delay of (± s.e.m.) human melanoma xenograft with BCNU and TNF. a, TNF 1 x 106 U kg-' daily;
b, TNF 1 x 106 U kg- b.d. - - -. * = control, 0 = BCNU 35 mg kg-', A = TNF, * = combination TNF + BCNU.
(Alexander et al., 1987; Das et al., 1989; Regenass et al.,
1987). It is important to assess such activity in vivo as well as
in vitro to confirm activity within the host and to exclude
significant toxicity. Such an interaction has been demon-
strated here in vivo for BCNU and TNF in syngeneic
tumours and in xenografts. Although the mechanism may be
related to enhanced direct cytotoxicity, in vivo host factors
such as tumour vasculature may also be relevant.
Tumour regression in C57 BL mice occurred at TNF doses
close to the maximum tolerated dose (MTD) for tumour
bearing animals. With the human melanoma xenografts the
dose of TNF had to be increased nearer to the MTD for this
strain, to achieve growth delay. It appears that increased
exposure to TNF in vivo may be important as a twice daily
dose schedule was more effective. This may have a phar-
macokinetic basis as TNF is rapidly cleared from serum
(Jones & Selby, 1990).
Data from phase I trials suggest that the therapeutic index
of TNF in man is small (Selby et al., 1987) and toxicity may
preclude its use in cancer patients. Certainly our data suggest
excess toxicity in tumour bearing animals and this may argue
for the use of TNF and other biological therapies in the
setting of minimal disease. The clinical application of TNF
may be increased by its use in combination therapy with
cytotoxic drugs. The mechanisms of such interactions require
further evaluation. However, even with combination therapy
it is likely that the necessary dose ofTNF will be close to the
maximum tolerated dose and combination therapy should be
approached cautiously because of the possibility of increased
toxicity to the host. A phase III randomised trial of BCNU
versus BCNU and TNF in patients with advanced melanoma
is now underway at the Royal Marsden Hospital to inves-
tigate the efficacy of TNF in combination with BCNU in
patients with disseminated malignant melanoma.
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